Cross-border cooperation to foster the resilience of clinical management in cancer patients by establishing best practices in personalized molecular-based diagnostics, treatment, and long-term care

Programme 2021 - 2027 Interreg VI-A IPA Romania Serbia

Date of latest update: 2025-09-26

Description

Description (EN):

CROSSCARE addresses the following common challenges in the cross-border region, as defined by the Joint Programme Strategy for Interreg IPA Romania-Serbia: approaching the issue of disparities in accessibility to health care services and low distribution of medical infrastructure and equipment; strengthening the effectiveness of health systems in order to reduce mortality; improvement in the quality of care for life-threatening conditions and cancer management, strengthening the effectiveness of health systems in order to reduce premature mortality. Specifically, the project addresses the issue of cancer, which is a major health threat in both countries in terms of incidence, prevalence and mortality. By purchasing new equipment and extending the capabilities of Expert System Software previously developed in the RORS-193 project, the partners will be able to implement medical project activities, i.e. harvesting the tumor and cell samples from cancer patients and subsequent genetic and immunophenotypic testing, in order to provide patients and their oncologists the precise diagnostic of tumors, that will make possible personalized treatments to be tailored, thus improving the chances of survival, life expectancy, and quality of life for cancer patients in both countries. The specific objective is to create guidelines and implement precision diagnostic procedures and personalized therapy for oncologic patients in the cross-border region. The precise diagnostic for 300 patients will be ensured by using advanced equipment and methodologies (NGS, flowcytometry, qRT-PCR, cytotoxicity assays) and surgical treatment in state-of-the-art operating facility. All data will be processed and interpreted by the algorithm-based Expert System Software which will provide therapeutic indications in solid tumors. During the project lifetime, the patients included in the study will benefit of the investments made in both partner institutions, while the results and conclusions of the medical activities will be incorporated into the study that will be submitted to the Romanian and Serbian Ministries of Health. Furthermore, new joint working procedures for sample harvesting, transport, and analysis of human biological samples will be created and will be available to the interested healthcare institutions from both countries. Publishing of two scientific articles and a PhD thesis and submitting an innovation patent are complementary activities derived from the medical work meant to add value to the project. At these add the know-how exchanges and medical seminars, while all work will be further supported by the Information and Publicity activities in order to maximize the impact of the project. The expected change at the end of the project is a better diagnostic and treatment of cancer through the use of the innovative precision diagnostic tool developed in CROSSCARE. The outputs to be delivered through the project work will be: 1. modernized equipment relevant for precise diagnostic and personalized treatment of oncologic patients and 2. extended capabilities of Expert System Software. By the end of the project, 300 patients from both Romania and Serbia will be direct beneficiaries of the precision diagnostic and surgical treatment with all data being processed and interpreted by the algorithm-based Expert System Software which will provide therapeutic indications in solid tumors. The project outputs delivered by this project will be used in partner countries, but can be extended to a wider region of Europe. Moreover, we aim in identifying a common target for all solid tumor, which can be further used in advancement of therapeutic strategies, including immunotherapies. Most of the activities will be implemented jointly at the same time or in sequence (surgery and harvesting of human biological samples, transport and genetic and immunophenotypic analysis, data processing and interpretation by the customized software, delivery of reports to patients). Since the most frequent types of cancer are the same in Romania and Serbia, this means a series of factors led to the predominance of these types in both countries, and CROSSCARE intends to identify a common tumor target and a set of mutated genes causing these tumors. The joint effort to solve a common health problem affecting tens of thousands of people every year in each of the two countries is the logical approach that will reduce the material and human resources needed to achieve the objectives of the current project proposal and will offer a joint solution to reducing cancer mortality and burden in both countries. The novelty of CROSSCARE solution will bring insights on the common genetic causes of cancer in the cross-border region, with a high potential of changing the current medical practice, at least for selected patients, ultimately leading to the implementation of precision diagnostics and treatment policies by the responsible authorities in both countries.

Actual Achievements (EN):

The activities performed during the first reporting period involved management and administrative tasks, including communication, and preparatory tasks for medical activities that start later in the project. Work contracts were concluded between each partner and their respective internal and external staff, as provided in Annex 15, Declaration of empowered bodies regarding the project team members. Later on, the two partners submitted on February 17, 2025, the Notification 1 regarding some changes of team members for LP1 and the change of the legal representative of PP2, which the Joint Secretariat accepted through „Acknowledgment of the Notification No. 1” on February 24, 2025. Both partners started activities A 1.1. Procurements, A 1.4. Surgery and harvesting of human biological samples, A 1.5. Developing and implementing joint working procedures for sample harvesting, transport, and analysis. In addition, LP1 started activity A.1.14. Information and Publicity Activities.

Project outputs: Modernized equipment relevant for precise diagnostic and personalized treatment of oncologic patients(EN)
Extended capabilities of Expert System Software(EN)

Thematic information

Health and social services Social inclusion and equal opportunities Knowledge and technology transfer

Priority: (VI-A_RO-SR_2) Social and economic development

Priority specific objective: RSO4.5. Ensuring equal access to health care and fostering resilience of health systems, including primary care, and promoting the transition from institutional to family-based and community-based care

Priority policy objective (Interreg specific objective): PO4 A more social and inclusive Europe implementing the European Pillar of Social Rights

Type of intervention: 129 Health equipment

Partners (2)

Lead Partner: Spitalul Clinic Județean de Urgență „Pius Brînzeu” Timișoara

PIC (Participant Identification Code): 895586451

Partner’s ID if not PIC: 4663448 | N/A | N/A (EN)

Department: OncoGen Centre

Address: Liviu Rebreanu, 300723 Timișoara, Romania

Department address: Liviu Rebreanu, 300723 Timișoara, Romania

Legal status: public

Organisation type: Hospitals and medical centres

Website: http://hosptm.ro

Total budget: EUR 1 130 298.73

Partner’s programme co-financing: EUR 960 753.92

Partner’s programme co-financing rate: 85.00%

Partner contribution: EUR 169 544.81

Contractors:

Name: SC ATEM WIN GROUP SRL
VAT registration or tax identification number: 45024840
Name: SC TECH SUPPORT SRL
VAT registration or tax identification number: RO22301403
Name: SC URC XEDOS SRL
VAT registration or tax identification number: 8977974
Name: SC EUROBIT SRL
VAT registration or tax identification number: 1825502

Opšta bolnica Đorđe Jovanović Zrenjanin

Name: Opšta bolnica Đorđe Jovanović Zrenjanin

PIC (Participant Identification Code): 105539565

Partner’s ID if not PIC: 105539565 | N/A | 08887535 (EN)

Address: Dr Vase Savića, 23000 Zrenjanin, Serbia

Department address: Dr Vase Savića, 23000 Zrenjanin, Serbia

Legal status: public

Organisation type: Hospitals and medical centres

Website: http://bolnica.org.rs/

Total budget: EUR 702 982.77

Partner’s programme co-financing: EUR 597 535.35

Partner’s programme co-financing rate: 85.00%

Partner contribution: EUR 105 447.42

Contractors:

Name: Consulting Directions PR
VAT registration or tax identification number: 110074564
Name: JELENA PETROV PR KTIRIO VRŠAC
VAT registration or tax identification number: 114714205

Partners map

Partners and Projects info

General Hospital Đorđe Jovanović Zrenjanin

Cross-border cooperation to foster the resilience of clinical management in cancer patients by establishing best practices in personalized molecular-based diagnostics, treatment, and long-term care

Partners and Projects info

Emergency Clinical County Hospital Pius Brinzeu Timisoara

Cross-border cooperation to foster the resilience of clinical management in cancer patients by establishing best practices in personalized molecular-based diagnostics, treatment, and long-term care

Lead partner

Project partner

Summary

Project name (EN): Cross-border cooperation to foster the resilience of clinical management in cancer patients by establishing best practices in personalized molecular-based diagnostics, treatment, and long-term care

Project acronym: CROSSCARE

Project ID: RORS00040

Project start date: 2024-11-28

Project end date: 2026-11-27

Project status: ongoing

Relevant linked projects:

Romania-Serbia joint initiative against cancer in cross-border region: improved diagnosis and treatment of malignant tumors (ROSECAN) project, eMS code RORS-193, Interreg IPA CBC Romania – Serbia 2014 – 2020 Programme (EN) | The current project builds on the experience gained in the ROSECAN project through which the OncoGen Centre of the Emergency Clinical County Hospital Timisoara was endowed with IT and medical equipment needed to implement the precise diagnostics in cancer achieved by using the Next Generation Sequencing (NGS) technology. The General Hospital “Đorđe Joanović'” Zrenjanin benefited from the ROSECAN project, through the participation of Serbian Ministry of Health, one of the project partners. Likewise, other 11 hospitals in Serbian programme area benefited of the ROSECAN project results together with two hospitals in Romania. This made it possible to create a network of 15 hospitals in the cross-border region which will be used in the current project in order to disseminate existing and new knowledge in the field of Oncology, particularly the precise, molecular-based diagnostics in cancer.
During the ROSECAN project implementation, the OncoGen medical researchers performed NGS on 50 tumor tissue samples. Other tests were also performed and the results of all analyses were introduced in the Expert System Software, a new and customised tool developed in the ROSECAN project. It is intended to further develop the Expert System Software in this project and to use it to analyse 300 more tumor tissue and cell samples with the aim to identify a common tumor target, i.e. the most common mutated genes leading to malignancies in the cross-border region.
This project will use the equipment purchased in both projects and the Expert System Software, therefore continuing the work and extending the scope of the ROSECAN project results. Medical activities performed by both partners will benefit a greater number of patients who will have access to the investments made in both projects. Finally, a set of important medical and scientific data will be available in view of implementing the precise diagnostics and treatment in the cross-border region and beyond. (EN), Oncoimmunotherapy with Natural Killers cells with chimeric antigen receptors (CAR-NK); POC 92/09/09/2016; ID: P_37_786; MySMIS code: 103662 (EN) | CAR-NK was the first Romanian project that advances the genetic engineering of cells of the immune system for the treatment of cancer. More specifically, Natural Killer (NK) cells, a particular type of white blood cells, normally responsible for eliminating emerging tumor cells, are armed with new genes encoding chimeric antigen receptors (CARs) that specifically bind molecules expressed by tumor cells surface. CARs are hybrid molecules that usually comprise different parts, mandatory being the targeting module for specific tumor antigen and intracellular modules that activate cytotoxic cellular pathways upon binding to the intended target. As certain types of cancers can express particular targets on their surface, immune cells such as NK or T cells can be modified to recognize and attack a specific type of malignant cell.
The overarching aim of the project was to develop in Romania, through in-house and international expertise, research and innovation-development as well as treatment capacities in the field of onco-immunology. The operational objectives of the project were to develop advanced personalized immunotherapies for various types of cancer based on CAR-NK cells and to create the first “off the shelf” human CAR-NK cell bank.
Through the present project we intend to identify novel targets on tumor cells, using the next generation sequencing, which can be further used in different immunotherapies to fight cancer, including NK-based autologous therapies (CAR construction). Moreover, CROSSCARE project aims to establish the immune status of oncologic patients, with main focus on cells with anti-tumor activities, such as T and NK cells. We will use our previous knowledge on NK and T cells to better characterize the function of these cells and to envision the anti-tumor role of these cellular population in overall immune response in cancer. (EN), 3D Bioprinting Techniques for Building Tissue Constructs that Mimic the Tumor Microenvironment (DeLIMIT); project code PN-III-P2-2.1-PED-2016-1422; 100PED/2017 (EN) | This project aimed to to build three-dimensional (3D) tissue constructs that mimic the tumor microenvironment. 3D constructs included a multicellular system whose structure resembles the tumor, and a layer of cells and extracellular matrix, which represents the tumor's vicinity. To build such tissue constructs, we relied on three-dimensional (3D) bioprinting, a domain of bottom-up tissue engineering. We developed models of 3D tumors in their environment, and validated them by morphological, phenotypic, genotypic and functional characterization. The project used two cell sources for microtissue printing: a standard cell culture line, and primary tumor cells. While the first option is more reproducible, the second might lead to a more realistic model of a tumor. For each cell type, we tested two methods of additive manufacturing: cell-laden hydrogel bioprinting and cell aggregate bioprinting. The obtained tumor models were validated in immunosuppressed nude mice. The bioprinted tissue constructs were ranked according to their ability to mimic the secretory behavior of in vivo tumors. Upon validation, the project's results could be applicable in the area of cancer therapy: the 3D tumor models will be used for personalized drug-design studies, in studies of tumor development, and in translational research that seeks to transfer in vitro results to in vivo clinical applications in a broad area of cancer therapy.
Within CROSSCARE we aim to analyze patient-derived immune and tumor microenvironment cells, so as to better understand the interaction between these cellular population, which is highly important for the anti-tumor response to targeted or conventional therapies. Apart from providing the patients and oncologists with full reports related to mutation-based therapies and immune status, identification of novel targets on tumor microenvironment cells could have a major impact on selecting the appropriate personalized therapy for the patients with solid tumors. (EN), Tumor-associated fibroblasts as novel therapeutic target in anti-tumor therapy – identification of origin, role and characteristic molecular markers; project code PN-II-ID-PCE-2011-3-0455; 318/2011 (EN) | Microenvironment has a key role in tumor development, so that identification of stromal targets for cancer therapeutics is of great interest and could provide strategies that will complement therapies directed against cancer cells. The failure of immune surveillance to prevent tumor development and the observation that effective therapies can become ineffective over time suggest that mechanisms exist, whereby tumors can escape the immune system. Tumor associated fibroblasts (TAFs), potentially originating from recruitment of resident tissue stem cells, bone marrow-derived mesenchymal stem cells (MSCs) or epithelial to mesenchymal transition within tumors, are important for tumor progression, providing both functional and structural supportive environment. The true origin, role, and biological characteristics of TAFs are not fully understood yet. The main objective of this project was to fully characterize TAFs obtained from solid tumors, to establish their origin and role within the tumor stroma. MSCs were used as normal/precursor cells to which the TAFs will be compared in order to identify specific marker, which would be used as target in prospective anti-tumor therapy designs. Cellular therapies in vitro prototype proposed by this project involves enhancement of human cytotoxic T lymphocytes (CTL) functionally active against TAF-derived specific antigen.
In the present project proposal we will anlyze the tumor microenvironment cells derived from the patients with solid tumors, especially tumor-associated fibroblasts (TAFs), with the purpose to identify a common antigen on these cells, which could become a generic therapeutic target in all solid tumors. With the use of NGS and spectral flowcytometric approaches, based on the methodology previously established, the analysis could go deeper and be more accurate in providing a therapeutic orientation for oncologic patients. (EN), Genetic engineering of tumor stem cells for modulation of immune response in non-viral cancer (ONCOSTEM), Programme PNCDI II-Partnerships, Project number: 41-019/2007 (EN) | The main objectives and results obtained within this project were as follows: isolation of a tumoral subpopulation capable of re-editation of tumor genesis; correlations with different stages and neoplasic types; phenotypic and genic expression of tumor stem cells (TSC); identification of signaling pathways involved in tumoral development of TSC and comparison to proliferation mechanisms of normal stem cells; obtaining genetic transformed cells in order to be recognized and attacked by immune system or differentiated towards a non-tumoral phenotype; quantification of anti-tumoral immunity modulation using genetic engineering techniques developed on animal model; development and patent of a controllable in vivo transfection method on animal model.
Synergic with the ONCOSTEM project, the present project proposal is proposing activities of genic expression quantitation and identification of genomic alterations which are amenable to known novel thrapies, or which can become target for immunotherapies to be developed. We will be able to stratify the tumor cells based on their genomic signature and subgroup them in TSC or other tumor cells. Moreover, the signaling pathways of the altered genes can also be targeted by different chemotherapeutic or small molecules inhibitors, resulting in decreased proliferation and development of the tumors as a whole (already existing in clinical practice are mutation-based molecules - kinase inhibitors, e.g.: lapatinib, pazopanib, alpelisib, etc.). (EN)

Total budget/expenditure: EUR 1 833 281.50

Total EU funding (amount): EUR 1 558 289.27

Total EU funding (co-financing rate): 85.00%

Co-financing sources:

IPA/IPA II/IPA III: Amount, EUR 1 558 289.27. Co-financing rate, 85.00%.

Investments, deliverables, policy contributions

(bullets are inserted automatically and may be incorrectly placed)

Deliverables:

Contracts for medical and IT equipment
Contract for Expert System Software
Contract for Communication activities
Translations by LP's project team members.
Contract for Reporting and Procurement expertise
Contracts for medical and IT equipment
Contract for Communication activities and project events
Contract for translations
Transport of harvested human biological samples
Study protocol elaborated for the oncologic patients, with inclusion and exclusion criteria
Informed consent form elaborated for the oncologic patients participating in the project
Protocol for blood samples collecting
Protocol for selecting and surgical removal of tumor samples to be analysed within the project
Value-added surgical procedures for oncologic patients
Joint Informed Consent Form
Working procedure for peripheral blood harvesting
Working procedure for fresh tumor tissue harvesting
Protocol for transport of biological samples
Working protocol for immunophenotypic analysis of sanguine nucleated cells
Working protocol for obtaining and culture expansion of tumor cells
Working protocol for cytotoxic assays
Joint working procedures booklet
Complete immune status analysis report
Complete genomic report of tumor samples
Classification of anti-tumor drugs based on effectiveness in destroying tumor cells
Expert System Software v2 report
Biobank of both blood and tumor tissue samples established in OncoGen facility
Upgraded Expert System Software v2
Documentation and source-code of ESS v2
Speakers presentations
Joint working procedures booklet revised
Medical scientific publications
PhD thesis
Joint agreement on IPR issues
Innovation patent documents
Study documentation for oncologic patients’ clinical management
Translated documents for LP1
Translated documents for PP2
Project Launch Conference
Project Closing Conference
Press conferences
International Medical Conference
Project website
Social media promotion
Promotional sets
Roll-up banners

Contribution to wider strategies and policies:

EUStrategyDanubeRegion Romania and Serbia are Danube Region Countries contributing to the “European Union Strategy for Danube Region” set out by the European Commission. By the activities proposed, this project contributes to Pillar 3, Building Prosperity in the Danube Region. The project includes research activities concomitant with the medical ones, by deriving and analysing the scientific data following medical tests on the tissue and cell samples from cancer patients in the cross-border region. The research results will be submitted to the Health Ministries in both countries in the form of a study on the genetic map of cancer in the region, helping to adapt public policies in this field, thus contributing to developing the knowledge on this group of diseases. It is also envisaged to publish two scientific articles, a PhD thesis and to submit a patent application by the end of the project. Thus, the project will contribute to achieving the goals of Priority 07, To develop the knowledge society through research, education and ICT: increased number of patent applications; enhanced regional research and education cooperation; increased annual output of co-publications.
Furthermore, by organizing medical seminars, know-how exchanges and an international medical conference, the project partners will not only increase their knowledge and skills, but will provide an opportunity to doctors in connected specialties, primarily Oncology, to improve their expertise and learn about the molecular diagnostics in cancer. These activities serve also the purpose of raising awareness among the oncologists in, but not limited to the cross-border region, regarding the benefits of genetic diagnostics and precise therapies in cancer. Therefore, these activities will contribute to reaching the objectives of Pillar 09, To invest in people and skills: increased quality and efficiency of training; promotion of lifelong learning; closer cooperation between institutions on bilateral level.
EuropeanGreenDeal The main goal of the European Green Deal is to improve the wellbeing and survival rates of plants, animals and humans, which entails a large-scale public health programme focused on prevention aspects. Another focus is on high-level research and innovation especially in the field of artificial intelligence, digital health and recommendation for good practices.
Our project will upgrade the Expert System Software developed in the RORS-193 project, which uses artificial intelligence, machine learning and algorithm-based precise diagnostic in order to give oncologic patients access to detailed and personalized diagnostic, as well as newest therapeutic medication.
The project partners will make use of digital health means to implement part of the medical activities. Both doctors and oncologic patients will have access to the medical investigation results by electronic means. The same is envisaged for the management and Communication activities.
By using electronic means of communication and reducing to minimum the printed materials, we also contribute to the European Green Deal goals.
TerritorialAgenda2030 Territorial Agenda 2030 defines two overarching objectives, a Just Europe and a Green Europe, which have six priorities for developing the European territory as a whole, along with all its places.
Out of the six priorities of the Just Europe objective, our project will make a contribution to three, as follows:
- Better balanced territorial development utilising Europe’s diversity. We will contribute by cooperating on an innovative solution that will help responding to global societal challenges, namely cancer. The precise diagnostic will help improving the lives of oncologic patients and will increase the innovation capacity of both partners in this project.
- Functional Regions - Convergent local and regional development, less inequality between places. We will make exchange of know-how and will establish best practices in diagnostic and treatment in Oncology.
- Integration beyond Borders - Easier living and working across national borders. By continuing and widening the cooperation between project partners, we will contribute to the goal of promotion of co-development, involving citizens across borders, for both medical personnel and oncologic patients.
Other Europe’s Beating Cancer Plan
Within the Horizon Europe Programme, the European Commission set forth the Europe’s Beating Cancer Plan in order to improve health and healthcare services across the European Union. As highlighted by the plan, the statistics envisage a 24% increase in cancer cases by 2035, calling to actions to reduce the burden of this group of diseases.
This project will contribute to the goal of “Improving early detection in cancer” by providing a precise diagnostic method that can be further developed to be used as a cancer screening method. Our goal is to identify a set of common mutated genes as target for a number of solid tumors with high incidence, prevalence and mortality in the cross-border region that will allow primarily for precise diagnostics in oncologic patients. Having knowledge of this set of common mutated genes, cancer screening programmes can add this newly developed tool to test highly susceptible individuals, meaning those with a family history suggestive for cancer, as well as other categories, based on new protocols.
In the same way, the project will contribute to the goal of “Equal access to cancer diagnosis in treatment” by the same diagnostic method, the results of which are the cornerstone of assigning a personalized therapy to a certain individual.
“Improving quality of life for cancer patients and survivors” is one of the most important missions of oncologists throughout the world and this project will contribute to it by creating new knowledge and by providing clinicians with critical information for the choice of the most effective therapy for each patient, i.e. a therapy with highest chances of success and the lowest possible toxicity.
Finally, the know-how exchanges, the international medical conference, the scientific papers and the PhD thesis, and the patent will contribute to increasing theoretical and clinical knowledge in this field.
Other EU Mission: Cancer
Together with the Europe’s Beating Cancer Plan, The Cancer Mission is devoted to providing a better understanding of cancer, allowing for earlier diagnosis and optimisation of treatment and improving cancer patients’ quality of life during and beyond their cancer treatment. The aim of EU Mission is improving the lives of more than 3 million people by 2030 through prevention, cure and for those affected by cancer, including their families, to live longer and better. The four objectives of the Cancer Mission are: understanding of cancer; prevention and early detection; diagnosis and treatment; quality of life for patients and their families. Our project addresses all four objectives and brings an innovative solution, namely the precise diagnostics of malignant tumors, therefore contributing to the understanding of cancer origin by identifying the mutated genes causing a given tumor. Precise diagnostic will result in personalized treatment. At the end of the project, a study will be made available to the Ministries of Health in Romania and Serbia highlighting a set of mutated genes responsible for the most common cancers in the cross-border area.
This project will also contribute to prevention and early detection of cancer by providing a precise diagnostic method that can be further developed to be used as a cancer screening method. Identifying the set of common mutated genes mentioned above, cancer screening programmes can be extended to include the newly developed tool in assessing the mutation burden of highly susceptible individuals with a family history suggestive of cancer, as well as other at risk categories, based on new protocols.
The project will contribute to improving the life quality of patients and families by creating new knowledge and by providing clinicians with critical information for the choice of the most effective therapy for each patient, i.e. a therapy with highest chances of success and the lowest possible toxicity.

Deliverable (other than infrastructural investment) areas:

România (RO), Timișoara, Liviu Rebreanu, 156, 300723
România (RO), Timișoara, Liviu Rebreanu, 156, 300723
Serbia (RS), Zrenjanin, Dr Vase Savića, 5, 23000

Programme Output Indicator:

PSO 03 - Investments in health care, family-based and community-based care services, Measurement unit: investments

Programme Result Indicator:

PSR 03 - Annual users of the supported investments in health care, family-based and community-based care services, Measurement unit: users/year

Project part of European Union Macro-Regional or Sea Basin Strategy: EUSDR

Information regarding the data in keep.eu on the programme financing this project

Financing programme

2021 - 2027 Interreg VI-A IPA Romania Serbia

Last month that data in keep.eu was retrieved from the Programme's website or received from the Programme

2025-09-26

No. of projects in keep.eu / Total no. of projects (% of projects in keep.eu)

32 / 32 (100%)

No. of project partnerships in keep.eu / Total no. of project partnerships (% of project partnerships in keep.eu)

91 / 91 (100%)

Notes on the data

Languages

Contact Form

Cross-border cooperation to foster the resilience of clinical management in cancer patients by establishing best practices in personalized molecular-based diagnostics, treatment, and long-term care

Description

Thematic information

Partners (2)

Partners map

Summary

Investments, deliverables, policy contributions

Information regarding the data in keep.eu on the programme financing this project

Disclaimer